About the Company
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ICPT News
Intercept Pharmaceuticals stock tumbles toward 11-month low after disappointing FDA committee vote
Shares of Intercept Pharmaceuticals Inc. tumbled 15.2% toward an 11-month low in premarket trading Monday, after the biopharmaceutical company said a U.S. Food and Drug Administration committee ...
Intercept Pharmaceuticals,
Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver ...
Intercept Pharmaceuticals Confirms Data Breach Resulting in Leaked SSNs, PHI and Financial Account Information
On February 22, 2024, Intercept Pharmaceuticals, Inc. (“Intercept”) filed a notice of data breach with the Attorney General of Massachusetts after discovering that an unauthorized party was ...
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare ...
The Rising Challenge for Intercept Pharmaceuticals: Analyst Downgrade Amid Ocaliva's DILI Concerns
Canaccord Genuity has lowered the price target for Intercept Pharmaceutical Inc (NASDAQ: ICPT) from $26 to $12, with a Hold rating. The analyst says Ocaliva, for PBC, is worth $16 per share ...
Intercept Pharmaceuticals: Do Not Expect PBC Sales To Save The Company
After last Friday’s unfavorable AdCom meeting, Intercept’s NASH candidate now appears dead on arrival. Some analysts have suggested that Intercept's valuation will be buttressed by their PBC ...
Intercept (ICPT) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Search Results for "intercept":
Intercept Pharmaceuticals, Inc. (NASDAQ:ALXN) for valuable returns.4 Stocks to Watch after the Massive Equifax (NYSE:EFX) HackCybersecurity stocks spiked on recent news of a data breach affecting ...
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 26, 2024 Acumen Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds ...
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as ...
Q4 2023 Acumen Pharmaceuticals Inc Earnings Call
Alex Braun; Head, IR; Acumen Pharmaceuticals, Inc. Dan O'Connell; CEO; Acumen Pharmaceuticals, Inc. Eric Siemers; Chief Medical Officer; Acumen Pharmaceuticals Inc Jim Doherty; President & Chief ...
Loading the latest forecasts...